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Abstract
Drugs active at G protein-coupled receptors (GPCRs) can differentially modulate either canonical
or non-canonical signaling pathways via a phenomenon known as functional selectivity or biased
signaling. We report biochemical studies that show that the hallucinogen lysergic acid
diethylamide (LSD), its precursor ergotamine (ERG) and related ergolines display strong
functional selectivity for β-arrestin signaling at the 5-hydroxytryptamine (5-HT) receptor 5-HT2B,
while being relatively unbiased at the 5-HT1B receptor. To investigate the structural basis for
biased signaling, we determined the crystal structure of the human 5-HT2B receptor bound to
ERG, and compared it with the 5-HT1B/ERG structure. Given the relatively poor understanding of
GPCR structure-function to date, insight into different GPCR signaling pathways are important to
better understand both adverse and favorable therapeutic activities.
Apart from canonical G protein mediated signaling, G protein-coupled receptors (GPCRs)
also activate non-canonical G protein-independent pathways, frequently mediated by β-
arrestins (1, 2). So-called ‘biased’ GPCR agonists differentially activate both signaling
pathways with distinct efficacies and potencies as compared to unbiased agonists that
activate both pathways equally (3). This preferential activation of one pathway over the
other has been termed “functional selectivity” or “signaling bias” (2–5). Depending on the
receptor, biased signaling patterns are key for mediating inflammation (6), apoptosis (7), and
many other processes (2). Biased ligands have been proposed to stabilize receptor
conformations that are distinct from those induced by unbiased ligands, and selectively
change the propensity of GPCR coupling to either G proteins or β-arrestin (2).
Agonist-induced changes in “trigger motifs” of GPCRs (8) near the binding pocket facilitate
large-scale helical movements that are accompanied by rearrangements in highly conserved
residues called “micro-switches” (9) that prime GPCRs for subsequent G protein binding
and activation (10). The structural features of a signaling biased receptor state remain
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elusive, and although complexes of two β-arrestin-biased ligands with the β1 adrenergic
receptor (β1AR) have been recently solved (11), they did not reveal activation-related
changes in the receptor.
To elucidate molecular and structural details of biased signaling, we characterized G
protein- and β-arrestin-mediated signaling at G protein-coupled serotonin (5-HT; 5-
hydroxytryptamine) receptors with several representative ergolines like LSD and ERG, and
solved the crystal structure of the 5-HT2B receptor in complex with ERG, which was
identified as a highly biased agonist for the 5-HT2B receptor (12).
To investigate potential differences of ergoline signaling at 5-HT receptors, we examined
three prototypical serotonin receptors that interact with distinct G proteins. The 5-HT1B
receptor inhibits cyclic adenosine monophosphate (cAMP) production through Gi, the 5-
HT2B receptor mediates phospholipase C activation through Gq, and the 5-HT7A receptor
stimulates cAMP production through Gs (13). We compared G protein- and β-arrestin-
mediated signaling at cloned human 5-HT1B and 5-HT2B receptors, and G protein-mediated
signaling at 5-HT7A receptors stimulated by selective and non-selective ligands in HEK293
cells (Fig. 1, table S1) (14).
LSD, and especially ERG displayed bias for β-arrestin signaling at 5-HT2B (Bias factors 101
and 228 respectively; Fig. 1D), minimal bias at 5-HT1B (Bias factors 5 and 25 respectively;
Fig. 1D), and G protein antagonism at 5-HT7A receptors (Fig. 1B, table S1). We also found
significant β-arrestin signaling bias for other ergolines, such as dihydroergotamine (DHE),
methylergonovine (MTE), pergolide (PER), and cabergoline (CAB) at the 5-HT2B receptor,
whereas all other evaluated compounds showed no significant bias (Fig. 1D). ERG and
DHE, both of which contain a large tripeptide moiety substitution at the amide scaffold,
displayed more extreme signaling bias at the 5-HT2B receptor compared to LSD.
To investigate the molecular details responsible for biased signaling, we crystallized an
engineered 5-HT2B receptor construct in complex with ERG, solved its structure at 2.7 Å
(figure S1, S2, table S3), and compared it to the structure of 5-HT1B/ERG reported in the
companion manuscript (15), as well as to other known unbiased active-state GPCR
structures.
Residues P5.50, I3.40 and F6.44 (16, 17), the “P-I-F” motif, form an interface between helix V,
helix III and helix VI near the base of the ligand binding pocket in the β2 adrenergic receptor
(β2AR) and many other aminergic receptors, including all 5-HT GPCRs. In the active-state
structures of β2AR (8, 18), a chain of conformational rearrangements occur in the P-I-F
residues, in which an inward shift of helix V residue P2115.50 is coupled with: (i) a rotamer
switch in I1213.40, (ii) a large movement of the F2826.44 side chain, and (iii) a corresponding
rotation of helix VI on the cytoplasmic side (8). The 5-HT1B and 5-HT2B receptor structures
display two different conformations of the P-I-F motif (Fig. 2). For the 5-HT1B receptor, we
observe that the P-I-F configuration is essentially identical to that of the active-state of
β2AR (β2AR-R*, PDB ID: 3SN6, (18)) (Fig. 2B). Whereas the 5-HT2B receptor adopts a
similar conformation of P2295.50 and I1433.40, the side-chain conformation of F3336.44 was
similar to that observed in the inactive β2AR (β2AR-R, PDB ID: 2RH1, (19)) (Fig. 2C,
figure S2B). The P-I-F motif, therefore, appears to be in an active-like conformation in the
5-HT1B structure, but only in an intermediate active conformation in the 5-HT2B receptor
structure.
At the cytoplasmic side of the receptors, GPCR activation is generally characterized by the
displacement of helices V, VI and VII (10). The magnitude of the helical motions depends
on the activation-state; for example, the outward displacement of the intracellular tip of
helix VI ranges between 3 and 14 Å, whereas helix VII shifts between 3 to 5 Å towards the
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receptor core (10, 18–22). These concerted rearrangements induce an opening of the helical
bundle at the cytoplasmic side, which facilitates the binding and subsequent activation of G
proteins. Analysis of the 5-HT1B and 5-HT2B receptor structures shows that the
conformation in the intracellular half of the helical bundle is notably shifted towards that
seen in active-state GPCR structures (Fig. 3, figures S3 and S4), and distinct from those of
inactive-state GPCR structures (Fig. 3, figures S5 and S6). In the 5-HT1B and 5-HT2B
receptor structures, the helix VI intracellular part is located at least 2 to 4 Å further away
from the receptor core than in the inactive-state structures of other aminergic GPCRs (figure
S5). This conformation of helix VI is close to the one observed in active-state structures of
the A2A adenosine receptor (A2AAR) (figure S3), and rhodopsin (Rho) (figure S4), though
the outward shift of the helix is smaller in magnitude compared to that of the G protein-
bound β2AR (Fig. 3A, 3C). The only difference that we observed in helix VI between 5-HT
receptor subtypes was a small clockwise rotation in the 5-HT1B receptor towards the active-
state that is absent in the 5-HT2B structure (Fig. 2B, 2C, 3A, 3C). Helix VII in both 5-HT
receptor structures also displays intermediate active-states when compared to β2AR (Fig.
3B, 3D), where it is shifted further towards the receptor core than in inactive-state structures
of other aminergic GPCRs (figure S6). Whereas the 5-HT2B/ERG receptor structure shows
less pronounced active-like changes in helix VI, helix VII appears to be in a more active
conformation than it is in the 5-HT1B/ERG receptor structure (Fig. 3B, 3D).
Another important aspect of GPCR activation are rearrangements of side chains in highly
conserved motifs D(E)/RY (helix III) and NPxxY (helix VII), which are referred to as
“micro-switches” (9). Thus, the D(E)/RY motif of all inactive-state and most active-state
GPCR structures shows an intact salt bridge between the side chains of D(E)3.49 and R3.50.
Importantly, this salt bridge is broken only in the active-state structures of β2AR-Gαβγ (18)
and Opsin-GαCT (21), where R3.50 interacts instead with the G protein and Gα peptide,
respectively. The salt bridge is preserved between the side chains of R1533.50 and D1523.49
in the 5-HT2B receptor structure, but it is broken in the 5-HT1B receptor structure (Fig. 4A,
4B, 4D, figure S2C). In the 5-HT1B receptor structure, the D1463.49 side chain forms a
hydrogen bond to Y157 in ICL2, and the R1473.50 side chain interacts with the main chain
carbonyl in a loop of the fusion protein BRIL (residue L1048), which is partially inserted
into the G protein binding crevice (Fig. 4A). Thus, the conformation of the D(E)RY motif
mimics the active state of β2AR in the 5-HT1B structure, but resembles the inactive state in
the 5-HT2B structure (Fig. 4A, 4C and figure S7).
The highly conserved NPxxY motif at the cytoplasmic end of helix VII is another key
micro-switch of GPCR activation (9). Upon GPCR activation, (i) the intracellular end of
helix VII moves towards the receptor core and (ii) a rotation of Y7.53 around the helical axis
moves the side chain further into the 7TM bundle (10). Both 5-HT receptor structures show
active-state conformations of the NPxxY motif when compared to β2AR, A2AAR and Rho
(Fig. 4D–E and figures S2D and S7), with more pronounced activation features in the 5-
HT2B receptor.
Our analysis indicates that the 5-HT1B/ERG structure has most of the attributes of a classical
agonist-induced active-like state, consistent with our biochemical findings that ERG is a
comparatively unbiased agonist at the 5-HT1B receptor. In contrast, the 5-HT2B/ERG
structure exhibits conformational characteristics of both the active- and inactive-state. The
structure of β2AR-Gαβγ complex, along with recent NMR and fluorescence studies of
β2AR, implicate helix VI predominantly in G protein signaling, whereas conformational
changes in helix VII are associated with enhanced β-arrestin signaling (18, 23, 24). Thus, an
active-like state in the helix VII conformation of the 5-HT2B receptor, but only partial
changes in helix VI, mirrors the strong β-arrestin bias of ERG at 5-HT2B receptors observed
in pharmacological assays.
Wacker et al. Page 3













A likely structural explanation for the distinct conformational features and biased
pharmacology of ERG between 5-HT1B and 5-HT2B receptors can be found in the region of
the extracellular loop 2 (ECL2) junction with helix V. In the 5-HT2B receptor structure,
E212-R213-F214 form an additional helical turn which is stabilized by a structured water
molecule and forms a sharp angle to the extracellular tip of helix V (Fig. 5). As a result, the
segment of ECL2 that connect helices III and V via the conserved disulfide bond is
shortened in the 5-HT2B receptor inducing an inward shift and creating a conformational
constraint on the position of the extracellular tip of helix V. Because of these
rearrangements, ERG forms additional hydrophobic contacts with M2185.39, L3476.58,
V3486.59, L3627.35 and K211ECL2 (figure S8A) and stabilizes a closer distance between
helices V and VI, which form hydrophobic contacts between L2195.40, V3486.59 and
L3496.60, along with a hydrogen bond between S2225.43 and N3446.45 (figure S8B). These
extensive ligand-mediated interactions between helices V and VI in the 5-HT2B/ERG
complex may be inferred to prevent rearrangements in helix VI and the corresponding
rotation of F6.44 (8), observed in the 5-HT1B receptor and structures of other active-state
GPCRs. The strengthened interactions of helix V and VI through ligand-mediated hydrogen
bonds to both helices have also been linked to inhibition of G protein signaling at β2AR by
the most efficacious inverse agonist (25).
Ergolines predominantly signal through β-arrestin pathways at 5-HT2B receptors, whereas
signaling at 5-HT1B receptors appears non-biased. The differential signaling patterns are
mirrored in the crystal structures, which show features of an intermediate active-state for the
5-HT1B receptor, and a β-arrestin-biased activation-state for the 5-HT2B receptor. We
propose a mechanism by which ERG stabilizes a conformation of the 5-HT2B receptor that
selectively interferes with G protein signaling (figure S9). The tripeptide moiety of ERG
appears to function as a negative allosteric regulator of G protein signaling at the 5-HT2B
receptor, as ERG exhibits strongly increased β-arrestin signaling bias compared to LSD and
MTE. Because both therapeutic (26) and adverse (27) drug effects have been associated with
β-arrestin recruitment by GPCRs, identifying the features of biased GPCR states by known
and yet to be discovered intracellular signaling proteins may facilitate the development of
safer and more effective therapeutics with selective signaling profiles.
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Distinct signaling properties of lysergic acid diethylamide (LSD) and ergotamine (ERG) at
5-HT1B, 5-HT7A and 5-HT2B receptors. We used luminescence-based assays to measure 5-
HT1B receptor mediated Gi activation and cAMP production; fluorescence-based calcium
mobilization assays to measure 5-HT2B receptor mediated Gq activation and β-arrestin
translocation-dependent luciferase reporter assays to measure 5-HT1B and 5-HT2B receptors
mediated β-arrestin recruitment, all in HEK293 derived cells. (A) Normalized
concentration-response studies for LSD and ERG at human cloned 5-HT1B receptor-
mediated activation of Gi and non-canonical (Arrestin) signaling. (B) Normalized
concentration-response studies for LSD and ERG at human cloned 5-HT7A receptor-
mediated activation of Gs signaling in the presence and absence of 5-Hydroxytryptamine (5-
HT). (C) Normalized concentration-response studies for LSD and ERG at human cloned 5-
HT2B receptor-mediated activation of Gq and non-canonical (Arrestin) signaling. The solid
circles for LSD-Gs signals are superimposed by the solid squares for ERG-Gs signals and
thus, not visible. (D) Mean β-arrestin bias factors were calculated for serotonergic agonists
(dihydroergotamine (DHE), methylergonovine (MTE), pergolide (PER) and cabergoline
(CAB)), at 5-HT2B and 5-HT1B receptors. Concentration-responses curves were fit to the
Black and Leff operational model to obtain transduction coefficients [Log(τ/KA)] for each
ligand at each corresponding pathway. The ΔLog(τ/KA) was then calculated with 5-HT as a
reference agonist for each pathway, and the ΔΔLog(τ/KA) was calculated between two
pathways for each ligand. The bias factor is unit-less and defined as 10ΔΔLog(τ/KA) (28).
Compounds with values close to one represent unbiased agonists while compounds with
large numerical values, typically >100, represent extremely biased agonists. *p<0.0001 via
two-way ANOVA comparing 5-HT2B vs 5-HT1B bias factors; N=3–6 separate experiments.
ERG, DHE and, to a lesser extent, LSD, MTE and PER show strong β-arrestin bias at 5-
HT2B receptor, but not 5-HT1B receptor.
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Trigger motif P-I-F displays active- and intermediate active-state for 5-HT1B and 5-HT2B
receptors, respectively. Residues of the P-I-F motif are highlighted in a dashed red circle.
(A) Overall architecture of the 5-HT2B receptor (green) bound to ERG (magenta); residues
of the P5.50 I3.40 F6.44 motif are illustrated in space-filling representation. (B) Alignment
between 5-HT1B receptor (grey), β2AR-R (magenta; PDB ID: 2RH1) and β2AR-R*(yellow;
PDB ID: 3SN6) indicates an activated P-I-F motif in the 5-HT1B/ERG structure. Black
arrows indicate likely rearrangements upon 5-HT1B receptor activation according to analysis
of β2AR. (C) Alignment between 5-HT2B receptor (green), β2AR-R (magenta) and β2AR-
R* (yellow) suggests intermediate active-state of the P-I-F motif in the 5-HT2B/ERG
structure, with F6.44 in an inactive conformation. Black arrows indicate likely
rearrangements upon 5-HT2B receptor activation according to analysis of β2AR.
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Structural alignment with β2AR-R and β2AR-R* reveals distinct active-state 7TM
conformations of the 5-HT1B and 5-HT2B receptor structures. All structures were analyzed
based on the last membrane embedded residue to minimize the effect of G proteins and
fusion partners on the relative helix positions (see supplementary section). Center panel
shows overall 7TM configuration of β2AR-R (magenta; PDB ID: 2RH1), β2AR-R*(yellow;
PDB ID: 3SN6), 5-HT1B (grey) and 5-HT2B (green) receptors aligned through helices I–IV.
Membrane boundaries are indicated by grey dots according to the OPM database (29). (A,
C) Intracellular view of helix V and helix VI in β2AR-R, β2AR-R* compared to (A) the 5-
HT1B, or (C) the 5-HT2B receptor. Residues on the intracellular side of the membrane have
been removed for better comparison of ligand-induced helical rearrangements (see main
text). Helix VI of the 5-HT1B and 5-HT2B receptors is in an intermediate active-state
compared to β2AR. (B, D) Side view of helix VII and helix VIII in β2AR-R, β2AR-R* and
(B) 5-HT1B receptor, or (D) 5-HT2B receptor. Helix VII of the 5-HT1B and 5-HT2B
receptors is in an intermediate active-state compared to β2AR, with more pronounced
activation features for the 5-HT2B receptor.
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Activation state of the D(E)/RY and NPxxY motifs in 5-HT1B and 5-HT2B receptors
compared to β2AR-R and β2AR-R*. Configuration of the D(E)/RY motif in (A) the 5-HT1B
receptor (grey), (B) the 5-HT2B receptor (green), (C) β2AR-R* (yellow; PDB ID: 3SN6) and
(D) β2AR-R (magenta; PDB ID: 2RH1). Residues of the G protein in β2AR-R* (C) and G
protein mimicking BRIL loop (A) are highlighted in orange. The conformation of the D(E)/
RY motif in the 5-HT1B receptor is similar to that observed in β2AR-R*, whereas the
configuration of the 5-HT2B receptor compares to that of β2AR-R. (E, F) Conformational
states of Y7.53 of the NPxxY motif and the proceeding residue 7.54 in β2AR-R, β2AR-R*
and (E) the 5-HT1B, or (F) 5-HT2B receptor. When compared to β2AR, the conformation of
the NPxxY motif in the 5-HT1B receptor is in an intermediate active-state, whereas the
configuration of the 5-HT2B receptor is similar to β2AR-R*.
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Structural differences in extracellular configuration of helix V between 5-HT1B and 5-HT2B
receptors likely explain β-arrestin functional selectivity at the 5-HT2B receptor. Side view
(left) and top view (right) of 5-HT1B (grey) and 5-HT2B (green) receptors shows a kink in
the extracellular end of helix V in the 5-HT2B receptor. A water molecule (red sphere) was
found to stabilize the kink through hydrogen bonds (grey dashed lines) with the E2125.33
main-chain carbonyl oxygen and the main-chain nitrogens of D2165.37 and G2155.36. Main-
chain atoms of both residues are shown as lines.
Wacker et al. Page 11
Science. Author manuscript; available in PMC 2014 May 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
